| P2093 | author name string | Claudia P Miller | |
| | Joya Chandra | |
| | Vidya Gopalakrishnan | |
| | Soumen Khatua | |
| | Wafik Zaky | |
| | Christa Manton | |
| P2860 | cites work | Pediatric medulloblastoma - update on molecular classification driving targeted therapies | Q21129295 |
| | The ubiquitin-proteasome proteolytic pathway: destruction for the sake of construction | Q24292709 |
| | E2F-dependent accumulation of hEmi1 regulates S phase entry by inhibiting APC(Cdh1) | Q24296663 |
| | Prophase destruction of Emi1 by the SCF(betaTrCP/Slimb) ubiquitin ligase activates the anaphase promoting complex to allow progression beyond prometaphase | Q24304123 |
| | ARF-BP1/Mule is a critical mediator of the ARF tumor suppressor | Q24306428 |
| | Myc protein is stabilized by suppression of a novel E3 ligase complex in cancer cells | Q24321642 |
| | Mdm2 promotes the rapid degradation of p53 | Q24322597 |
| | FBXL2- and PTPL1-mediated degradation of p110-free p85β regulatory subunit controls the PI(3)K signalling cascade | Q24338848 |
| | 26S proteasomes and immunoproteasomes produce mainly N-extended versions of an antigenic peptide | Q24535312 |
| | mTOR: from growth signal integration to cancer, diabetes and ageing | Q24633662 |
| | The ubiquitin proteasome system in neuropathology | Q24644208 |
| | Origin and function of ubiquitin-like proteins | Q24651141 |
| | Comprehensive genomic characterization defines human glioblastoma genes and core pathways | Q24656128 |
| | The role of the ubiquitin proteasome system in cerebellar development and medulloblastoma | Q26782159 |
| | Structural basis for the activation of 20S proteasomes by 11S regulators | Q27628418 |
| | Smoothened mutation confers resistance to a Hedgehog pathway inhibitor in medulloblastoma. | Q27851485 |
| | Genome sequencing of SHH medulloblastoma predicts genotype-related response to smoothened inhibition | Q27852966 |
| | The ubiquitin system | Q27860803 |
| | CDC20 and CDH1: a family of substrate-specific activators of APC-dependent proteolysis. | Q27930914 |
| | A subcomplex of the proteasome regulatory particle required for ubiquitin-conjugate degradation and related to the COP9-signalosome and eIF3. | Q27936509 |
| | Interaction between ubiquitin-protein ligase SCFSKP2 and E2F-1 underlies the regulation of E2F-1 degradation | Q28137846 |
| | SKP2 is required for ubiquitin-mediated degradation of the CDK inhibitor p27 | Q28137860 |
| | Control of meiotic and mitotic progression by the F box protein beta-Trcp1 in vivo | Q28177348 |
| | N-myc is essential during neurogenesis for the rapid expansion of progenitor cell populations and the inhibition of neuronal differentiation | Q28207748 |
| | Overexpression of the anaphase promoting complex/cyclosome inhibitor Emi1 leads to tetraploidy and genomic instability of p53-deficient cells | Q28253606 |
| | Introduction to NF-kappaB: players, pathways, perspectives | Q28271022 |
| | The ubiquitin ligase HectH9 regulates transcriptional activation by Myc and is essential for tumor cell proliferation | Q28280330 |
| | The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation | Q28280958 |
| | Subtypes of medulloblastoma have distinct developmental origins | Q28300616 |
| | Pharmacological activation of the p53 pathway by nutlin-3 exerts anti-tumoral effects in medulloblastomas | Q36048192 |
| | Targeting the mTOR-DEPTOR pathway by CRL E3 ubiquitin ligases: therapeutic application | Q36062128 |
| | Inhibition of PI3K-Akt-mTOR signaling in glioblastoma by mTORC1/2 inhibitors | Q36108972 |
| | It Takes 15 to Tango: Making Sense of the Many Ubiquitin Ligases of p53. | Q36387588 |
| | A phase I trial of vorinostat and bortezomib in children with refractory or recurrent solid tumors: a Children's Oncology Group phase I consortium study (ADVL0916) | Q36438027 |
| | Induction of cell death by the novel proteasome inhibitor marizomib in glioblastoma in vitro and in vivo | Q36500531 |
| | Post-transcriptional down-regulation of Atoh1/Math1 by bone morphogenic proteins suppresses medulloblastoma development | Q36509989 |
| | HER2 stabilizes EGFR and itself by altering autophosphorylation patterns in a manner that overcomes regulatory mechanisms and promotes proliferative and transformation signaling | Q36511804 |
| | Functional evaluation of therapeutic response for a mouse model of medulloblastoma | Q36630089 |
| | Cell survival, cell death and cell cycle pathways are interconnected: implications for cancer therapy | Q36736714 |
| | Nuclear factor-kappaB in development, prevention, and therapy of cancer | Q36743433 |
| | Dominant-negative mutants of platelet-derived growth factor revert the transformed phenotype of human astrocytoma cells | Q36826672 |
| | NFKBIA deletion in glioblastomas | Q36839660 |
| | The emerging role of Wnt signaling in the pathogenesis of acute myeloid leukemia. | Q36842360 |
| | Marizomib activity as a single agent in malignant gliomas: ability to cross the blood-brain barrier | Q36893244 |
| | Subgroup-specific prognostic implications of TP53 mutation in medulloblastoma | Q36929844 |
| | Bortezomib for the treatment of mantle cell lymphoma | Q36944390 |
| | Acquisition of granule neuron precursor identity is a critical determinant of progenitor cell competence to form Shh-induced medulloblastoma | Q37002410 |
| | Marizomib, a proteasome inhibitor for all seasons: preclinical profile and a framework for clinical trials | Q37017342 |
| | Homeostatic functions of the p53 tumor suppressor: regulation of energy metabolism and antioxidant defense | Q37107268 |
| | Medulloblastoma stem cells | Q37186416 |
| | Targeted inhibition of the immunoproteasome is a potent strategy against models of multiple myeloma that overcomes resistance to conventional drugs and nonspecific proteasome inhibitors | Q37187543 |
| | The HECT-domain ubiquitin ligase Huwe1 controls neural differentiation and proliferation by destabilizing the N-Myc oncoprotein | Q37187752 |
| | Bortezomib-induced peripheral neuropathy in multiple myeloma: a comprehensive review of the literature | Q37198339 |
| | Paediatric and adult glioblastoma: multiform (epi)genomic culprits emerge | Q37729676 |
| | Treatment-related peripheral neuropathy in multiple myeloma: the challenge continues | Q37798898 |
| | Deubiquitinases in the regulation of NF-κB signaling | Q37814068 |
| | Novel functions for the anaphase-promoting complex in neurobiology. | Q37857958 |
| | Treatment of high-grade glioma in children and adolescents | Q37904503 |
| | Hedgehog/Gli control by ubiquitination/acetylation interplay. | Q37990685 |
| | Mdm2 and MdmX partner to regulate p53. | Q38016717 |
| | The ubiquitin-proteasome system in glioma cell cycle control | Q38028002 |
| | The complexity of NF-κB signaling in inflammation and cancer | Q38126565 |
| | Oncoprotein stabilization in brain tumors. | Q38156100 |
| | Proteasome Activation by Small Molecules. | Q38702001 |
| | Functionally defined therapeutic targets in diffuse intrinsic pontine glioma | Q28833173 |
| | Mechanisms of Wnt signaling in development | Q29547537 |
| | Role of platelet-derived growth factors in physiology and medicine | Q29615222 |
| | PI3K pathway alterations in cancer: variations on a theme | Q29615530 |
| | Modes of p53 regulation | Q29615657 |
| | Structure and function of the blood-brain barrier | Q29615699 |
| | Role of the ubiquitin-proteasome pathway in regulating abundance of the cyclin-dependent kinase inhibitor p27 | Q29617346 |
| | Convergence of Wnt, beta-catenin, and cadherin pathways | Q29619504 |
| | Building ubiquitin chains: E2 enzymes at work | Q29619578 |
| | Inflammation meets cancer, with NF-κB as the matchmaker | Q29620242 |
| | Brain tumor epidemiology: consensus from the Brain Tumor Epidemiology Consortium | Q30481789 |
| | Discrete cleavage motifs of constitutive and immunoproteasomes revealed by quantitative analysis of cleavage products | Q30685494 |
| | Salinosporamide A: a highly cytotoxic proteasome inhibitor from a novel microbial source, a marine bacterium of the new genus salinospora. | Q30764187 |
| | The catalytic sites of 20S proteasomes and their role in subunit maturation: a mutational and crystallographic study | Q30779094 |
| | Velcade: U.S. FDA approval for the treatment of multiple myeloma progressing on prior therapy | Q33357936 |
| | A phase 2 study of two doses of bortezomib in relapsed or refractory myeloma | Q33363081 |
| | Phase I study of the proteasome inhibitor bortezomib in pediatric patients with refractory solid tumors: a Children's Oncology Group study (ADVL0015). | Q33363903 |
| | United States Food and Drug Administration approval summary: bortezomib for the treatment of progressive multiple myeloma after one prior therapy | Q33371230 |
| | Phase 1 clinical trial of bortezomib in adults with recurrent malignant glioma | Q33388541 |
| | A phase I study of bortezomib and temozolomide in patients with advanced solid tumors. | Q33396761 |
| | Phase II trial of vorinostat in combination with bortezomib in recurrent glioblastoma: a north central cancer treatment group study | Q33398291 |
| | Selective small molecule compounds increase BMP-2 responsiveness by inhibiting Smurf1-mediated Smad1/5 degradation | Q33614939 |
| | Differential Effects of the Proteasome Inhibitor NPI-0052 against Glioma Cells. | Q33655371 |
| | Bortezomib reverses a post-translational mechanism of tumorigenesis for patched1 haploinsufficiency in medulloblastoma. | Q33772264 |
| | Bortezomib-induced sensitization of malignant human glioma cells to vorinostat-induced apoptosis depends on reactive oxygen species production, mitochondrial dysfunction, Noxa upregulation, Mcl-1 cleavage, and DNA damage | Q33798624 |
| | Inhibition of nuclear factor kappa-B signaling reduces growth in medulloblastoma in vivo | Q33872837 |
| | Integrated molecular genetic profiling of pediatric high-grade gliomas reveals key differences with the adult disease | Q33990951 |
| | Crystal structures of Salinosporamide A (NPI-0052) and B (NPI-0047) in complex with the 20S proteasome reveal important consequences of beta-lactone ring opening and a mechanism for irreversible binding | Q33994984 |
| | Bortezomib-induced unfolded protein response increases oncolytic HSV-1 replication resulting in synergistic antitumor effects | Q34045104 |
| | Proteolysis-independent regulation of PI3K by Cbl-b-mediated ubiquitination in T cells. | Q34088521 |
| | Catalytic activities of the 20 S proteasome, a multicatalytic proteinase complex | Q34092896 |
| | Molecular subgroups of medulloblastoma: an international meta-analysis of transcriptome, genetic aberrations, and clinical data of WNT, SHH, Group 3, and Group 4 medulloblastomas | Q34167499 |
| | Protein expression of platelet-derived growth factor receptor correlates with malignant histology and PTEN with survival in childhood gliomas | Q34191508 |
| | Genome sequencing of pediatric medulloblastoma links catastrophic DNA rearrangements with TP53 mutations | Q34248736 |
| | Coexpression of platelet-derived growth factor (PDGF) and PDGF-receptor genes by primary human astrocytomas may contribute to their development and maintenance | Q34255631 |
| | ATP-dependent incorporation of 20S protease into the 26S complex that degrades proteins conjugated to ubiquitin | Q34310551 |
| | Somatic mutations of the Parkinson's disease-associated gene PARK2 in glioblastoma and other human malignancies | Q39009613 |
| | Histone H3.3. mutations drive pediatric glioblastoma through upregulation of MYCN. | Q39173934 |
| | Phase 1 clinical trial of the novel proteasome inhibitor marizomib with the histone deacetylase inhibitor vorinostat in patients with melanoma, pancreatic and lung cancer based on in vitro assessments of the combination | Q39443721 |
| | FBXW7 targets mTOR for degradation and cooperates with PTEN in tumor suppression | Q39904718 |
| | Ubiquitin-independent degradation of cell-cycle inhibitors by the REGgamma proteasome | Q40115986 |
| | Degradation of Id2 by the anaphase-promoting complex couples cell cycle exit and axonal growth. | Q40261081 |
| | Phosphatidylinositol 3'-kinase/AKT signaling is activated in medulloblastoma cell proliferation and is associated with reduced expression of PTEN. | Q40278543 |
| | Vitamin C inactivates the proteasome inhibitor PS-341 in human cancer cells | Q40333252 |
| | Activity probe for in vivo profiling of the specificity of proteasome inhibitor bortezomib | Q40431708 |
| | Proteasome inhibitor PS-341 causes cell growth arrest and apoptosis in human glioblastoma multiforme (GBM). | Q40494554 |
| | Bortezomib Treatment Sensitizes Oncolytic HSV-1-Treated Tumors to NK Cell Immunotherapy | Q40498974 |
| | Pharmacodynamic and efficacy studies of the novel proteasome inhibitor NPI-0052 (marizomib) in a human plasmacytoma xenograft murine model | Q40550633 |
| | Mechanisms of muscle wasting. The role of the ubiquitin-proteasome pathway | Q41249327 |
| | Integrated analysis of pediatric glioblastoma reveals a subset of biologically favorable tumors with associated molecular prognostic markers | Q41264935 |
| | The interferon-gamma-inducible 11 S regulator (PA28) and the LMP2/LMP7 subunits govern the peptide production by the 20 S proteasome in vitro | Q41283840 |
| | A mouse model of the most aggressive subgroup of human medulloblastoma | Q41484437 |
| | The role of human glioma-infiltrating microglia/macrophages in mediating antitumor immune responses | Q41779891 |
| | Quantification and pharmacokinetics of blood-brain barrier disruption in humans | Q42552409 |
| | Hedgehog signaling promotes the degradation of tumor suppressor Sufu through the ubiquitin-proteasome pathway | Q42806637 |
| | Ubiquitylation of the amino terminus of Myc by SCF(β-TrCP) antagonizes SCF(Fbw7)-mediated turnover | Q42820389 |
| | Inverse relationship between p27/Kip.1 and the F-box protein Skp2 in human astrocytic gliomas by immunohistochemistry and Western blot | Q44074040 |
| | A human brain tumor-derived PDGFR-alpha deletion mutant is transforming | Q44303994 |
| | Endocytosis of Receptor Tyrosine Kinases Is Driven by Monoubiquitylation, Not Polyubiquitylation | Q44420471 |
| | The F-box protein Skp2 participates in c-Myc proteosomal degradation and acts as a cofactor for c-Myc-regulated transcription | Q44455864 |
| | PDGF stimulates the massive expansion of glial progenitors in the neonatal forebrain | Q44704841 |
| | Suppressor of fused controls mid-hindbrain patterning and cerebellar morphogenesis via GLI3 repressor. | Q44818348 |
| | Analysis of the activation status of Akt, NFkappaB, and Stat3 in human diffuse gliomas | Q44927492 |
| | A selective inhibitor of the immunoproteasome subunit LMP7 blocks cytokine production and attenuates progression of experimental arthritis. | Q45969598 |
| | Leaving groups prolong the duration of 20S proteasome inhibition and enhance the potency of salinosporamides | Q46380819 |
| | Tyrosine kinase expression in pediatric high grade astrocytoma | Q46809466 |
| | Bone morphogenetic protein 2 opposes Shh-mediated proliferation in cerebellar granule cells through a TIEG-1-based regulation of Nmyc. | Q46939297 |
| | Amplification of KIT, PDGFRA, VEGFR2, and EGFR in gliomas | Q48327574 |
| | Hotspot mutations in H3F3A and IDH1 define distinct epigenetic and biological subgroups of glioblastoma | Q48329991 |
| | Phase I trial of dose-escalating metronomic temozolomide plus bevacizumab and bortezomib for patients with recurrent glioblastoma | Q48473042 |
| | Carfilzomib or bortezomib in relapsed or refractory multiple myeloma (ENDEAVOR): an interim overall survival analysis of an open-label, randomised, phase 3 trial | Q48599660 |
| | Bortezomib stabilizes NOXA and triggers ROS-associated apoptosis in medulloblastoma. | Q53243559 |
| | Prevention of experimental colitis by a selective inhibitor of the immunoproteasome. | Q53320286 |
| | Beta-catenin nuclear activation: common pathway between Wnt and growth factor signaling in vascular smooth muscle cell proliferation? | Q53583848 |
| | Biological and clinical heterogeneity of MYCN-amplified medulloblastoma. | Q55462417 |
| | Proteasome inhibitors: from research tools to drug candidates | Q34341985 |
| | New cytotoxic salinosporamides from the marine Actinomycete Salinispora tropica | Q34437864 |
| | A novel orally active proteasome inhibitor induces apoptosis in multiple myeloma cells with mechanisms distinct from Bortezomib | Q34467271 |
| | Tumor suppression by the Fbw7 ubiquitin ligase: mechanisms and opportunities | Q34488856 |
| | Crystal structure of the boronic acid-based proteasome inhibitor bortezomib in complex with the yeast 20S proteasome | Q34501396 |
| | FBXW7 influences murine intestinal homeostasis and cancer, targeting Notch, Jun, and DEK for degradation | Q34577722 |
| | APC/CCdc20targets E2F1 for degradation in prometaphase | Q34619596 |
| | Chemotherapy-induced peripheral neuropathy: prevention and treatment strategies | Q34788181 |
| | Bortezomib induces nuclear translocation of IκBα resulting in gene-specific suppression of NF-κB--dependent transcription and induction of apoptosis in CTCL. | Q34802998 |
| | Roles of F-box proteins in cancer | Q35012352 |
| | PDGF autocrine stimulation dedifferentiates cultured astrocytes and induces oligodendrogliomas and oligoastrocytomas from neural progenitors and astrocytes in vivo | Q35080265 |
| | Molecular subgroups of medulloblastoma | Q35101347 |
| | NF-kappaB and cancer: how intimate is this relationship | Q35143597 |
| | Proteomic screen reveals Fbw7 as a modulator of the NF-κB pathway. | Q35160414 |
| | Escape from Cbl-mediated downregulation: a recurrent theme for oncogenic deregulation of receptor tyrosine kinases | Q35169572 |
| | Therapeutic effect of neural stem cells expressing TRAIL and bortezomib in mice with glioma xenografts | Q35175677 |
| | Shh signaling protects Atoh1 from degradation mediated by the E3 ubiquitin ligase Huwe1 in neural precursors. | Q35194132 |
| | Specific and prolonged proteasome inhibition dictates apoptosis induction by marizomib and its analogs | Q35269634 |
| | Activation of the heat-stable polypeptide of the ATP-dependent proteolytic system | Q35414574 |
| | Role of protein ubiquitylation in regulating endocytosis of receptor tyrosine kinases | Q35691555 |
| | APC mutations in sporadic medulloblastomas | Q35745470 |
| | Genetic pathways to primary and secondary glioblastoma | Q35757144 |
| | The development of proteasome inhibitors as anticancer drugs | Q35773857 |
| | An animal model of MYC-driven medulloblastoma | Q35774418 |
| | Fbxw7α- and GSK3-mediated degradation of p100 is a pro-survival mechanism in multiple myeloma | Q35919057 |
| | Myc proteins in brain tumor development and maintenance | Q35920494 |
| | Bortezomib induces apoptosis and growth suppression in human medulloblastoma cells, associated with inhibition of AKT and NF-ĸB signaling, and synergizes with an ERK inhibitor | Q35925413 |
| | Pediatric and adult sonic hedgehog medulloblastomas are clinically and molecularly distinct | Q35960250 |
| | Proteasome inhibition with bortezomib induces cell death in GBM stem-like cells and temozolomide-resistant glioma cell lines, but stimulates GBM stem-like cells' VEGF production and angiogenesis | Q35997166 |
| | Mobilizing the proteolytic machine: cell biological roles of proteasome activators and inhibitors | Q36010873 |
| | The Fbw7 and betaTRCP E3 ubiquitin ligases and their roles in tumorigenesis | Q36029051 |
| | SCF(Fbw7) modulates the NFkB signaling pathway by targeting NFkB2 for ubiquitination and destruction. | Q36033829 |
| P433 | issue | 4 | |
| P921 | main subject | brain tumor | Q233309 |
| P304 | page(s) | 617-633 | |
| P577 | publication date | 2017-10-25 | |
| P1433 | published in | Cancer and Metastasis Reviews | Q2647982 |
| P1476 | title | The ubiquitin-proteasome pathway in adult and pediatric brain tumors: biological insights and therapeutic opportunities | |
| P478 | volume | 36 | |